For US Healthcare Professionals Only
Publications
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.
*Includes seizure clusters and acute or prolonged seizures
197 result(s)
phase
4/RWE
FINTEPLA® (fenfluramine)
Dravet Syndrome, Lennox-Gastaut Syndrome
Prolonged fenfluramine use in open-label studies of Dravet or Lennox-Gastaut syndromes: long-term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness
phase
3
RYSTIGGO® (rozanolixizumab-noli)
Generalized Myasthenia Gravis
Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions
pre-clinical
Generalized Myasthenia Gravis
The uptake, intracellular trafficking and recycling of FcRn-blocking therapeutics in human endothelial cells in vitro
phase
4/RWE
FINTEPLA® (fenfluramine)
Dravet Syndrome
Healthcare resource utilization and persistence in children and adults with Dravet syndrome receiving fenfluramine: a retrospective analysis using United States claims data
phase
2
KYGEVVI® (doxecitine and doxribtimine)
Thymidine Kinase 2 Deficiency
Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency
phase
4/RWE
Thymidine Kinase 2 Deficiency
Disease burden of untreated thymidine kinase 2 deficiency: insights from a large patient dataset
phase
4/RWE
Generalized Myasthenia Gravis
Prevalence and characteristics of patients with seronegative myasthenia gravis
phase
1
KYGEVVI® (doxecitine and doxribtimine)
Thymidine Kinase 2 Deficiency
Effect of renal impairment on the pharmacokinetics and safety of doxecitine and doxribtimine: a single-dose phase 1 study
phase
4/RWE
Generalized Myasthenia Gravis
Advancing Care in Myasthenia Gravis: What Can We Learn From the Multiple Sclerosis Community?